换一批
换一批Mortality at 1 year for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularization: do tirofiban and ReoPro give similar efficacy outcomes at trial 1-year follow-up.
第一作者：
Debabrata,Mukherjee
第一单位：
Division of Cardiovascular Medicine, Gill Heart Institute, University of Kentucky, Lexington, KY 40536-0200, USA. mukherjee@uky.edu
作者：
主题词
血管成形术, 气囊, 冠状动脉(Angioplasty, Balloon, Coronary);抗体, 单克隆(Antibodies, Monoclonal);药物疗法, 联合(Drug Therapy, Combination);女(雌)性(Female);随访研究(Follow-Up Studies);人类(Humans);免疫球蛋白Fab片段(Immunoglobulin Fab Fragments);男(雄)性(Male);中年人(Middle Aged);心肌梗死(Myocardial Infarction);心肌血管重建术(Myocardial Revascularization);血小板聚集抑制剂(Platelet Aggregation Inhibitors);支架(Stents);存活率分析(Survival Analysis);治疗结果(Treatment Outcome);酪氨酸(Tyrosine)
DOI
10.1093/eurheartj/ehi459
PMID
16107485
发布时间
2018-12-01
- 浏览107
European heart journal
2524-8页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
